Momenta, Sialix deal

Sialix granted Momenta an option to license a preclinical mAb program against cancer-specific glycans containing non-human sialic acid N-glycolylneuraminic acid (Neu5Gc). Sialix declined to disclose details. Momenta could not be reached for details. ...